New drug research and development of Shuanglu pharmaceutical industry focuses on aging related varieties

Liang Shujie, board secretary of Shuanglu pharmaceutical Liang Shujie introduced in detail the progress of the company's reserve varieties: it is expected that the new dosage form will be produced in 2 or 3 months later or by the end of this year The patented Dashti Ni will be approved by the end of this year The glutathione is currently being verified in the Beijing Bureau and transferred to the National Bureau after examination and approval The product will be available in 6 and July next year Si capsule is in the third phase of clinical practice, and it will be declared for production within two years; sl103 monoclonal antibody for rheumatoid arthritis treatment may also get clinical approval this year; the heavy weight 23 price vaccine has been declared for clinical practice She added that in the field of monoclonal antibodies, the company has nearly 10 varieties at different stages, one of which has been declared for clinical application, and 4-5 of which are in preclinical research "However, the specific varieties are still in the confidential stage." The research and development process of the company has been more and more folded In March this year, many new drugs, such as the Fu Ji complex gel, dasatinib, valsartan, amlodipine and pamidronic acid two sodium, were found to be "suspended" This has also attracted the attention of the company Liang Shujie said that although there are about ten varieties to be applied for, "if approved, it depends on the review speed and efficiency of the drug regulatory bureau" Before 2005, the company could get more than 20 approvals a year, but now the review process is very slow, and the number of new drugs approved by the company is relatively small every year.